BLASUBCUTANEOUSINJECTABLE
Approved
May 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
GONAL-F RFF REDI-JECT (follitropin) by Merck & Co. is (fsh), the active component in gonal-f rff redi-ject , is required for normal follicular growth, follicular maturation, and gonadal steroid production. Approved for infertility, ovulation induction, controlled ovarian stimulation and 5 more indications. First approved in 2004.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GONAL-F RFF REDI-JECT is a recombinant follicle-stimulating hormone (FSH) indicated for ovulation induction and controlled ovarian stimulation in infertility treatment. It works by stimulating ovarian follicular growth and maturation in women without primary ovarian failure, requiring hCG co-administration to trigger final follicle rupture. Inter-patient variability in FSH response necessitates individualized dosing and close monitoring.
LOE Approaching
As LOE approaches, the brand team will shift focus toward lifecycle extension strategies and market defense against biosimilar entry; expect reduced headcount and transition to managed-care focused roles.
Mechanism of Action
(FSH), the active component in GONAL-f RFF Redi-ject , is required for normal follicular growth, follicular maturation, and gonadal steroid production. The level of FSH is critical for the onset and duration of follicular development, and consequently for the timing and number of follicles reaching…
Pharmacologic Class:
Gonadotropin
Indications (8)
Worked on GONAL-F RFF REDI-JECT at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.